Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunovant, Inc.IMVT · Entity 3632 | Chief Financial Officer | April 16, 2025 | April 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunovant, Inc.
Report date April 16, 2025 · Filed April 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 396,774 |
Reported balance
After 2025-04-16 transaction · row 1
1 source rowRow 1 · 2025-04-16 · Sale · Disposed 2,993 · Balance 396,774 F1: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on April 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 - $15.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on April 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 - $15.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2025 Filed Apr 17, 2025 20:08 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,993 | $14.89 | $44,565.77 |
DisclosureSEC source: 0001764013-25-000076 · wk-form4_1744920500.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,774 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on April 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 - $15.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 20:06 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,050 | $12.99 | $52,609.50 |
DisclosureSEC source: 0001764013-25-000067 · wk-form4_1744401967.xml · nonDerivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 399,767 F3 · shares: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,938 of these RSUs vested on April 4, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 - $13.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 09, 2025 Filed Apr 11, 2025 20:06 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 7,013 | $12.99 | $91,098.87 |
DisclosureSEC source: 0001764013-25-000067 · wk-form4_1744401967.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 403,817 F1 · shares: On April 2, 2024, the holder was granted 54,978 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 4, 2024, of which 13,744 of these RSUs vested on April 2, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 - $13.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:48 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 125,180 | $0.00 Strike: $15.20 | $0.00 |
DisclosureSEC source: 0001764013-25-000051 · wk-form4_1743713294.xml · derivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,180 Underlying: Common Stock · 125,180 shares Expires 2035-04-01 F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 1, 2026 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:48 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 88,878 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-25-000051 · wk-form4_1743713294.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,830 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 1, 2026, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,814 | $20.86 | $58,700.04 |
DisclosureSEC source: 0001764013-25-000031 · wk-form4_1740171904.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,952 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on February 17, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.51 - $21.09 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 109 | $24.19 | $2,636.71 |
DisclosureSEC source: 0001764013-25-000014 · wk-form4_1737147952.xml · nonDerivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,766 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.13 - $24.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:05 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,189 | $23.81 | $52,120.09 |
DisclosureSEC source: 0001764013-25-000014 · wk-form4_1737147952.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,875 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on January 12, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.13 - $24.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:12 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,105 | $24.10 | $98,930.50 |
DisclosureSEC source: 0001764013-25-000004 · wk-form4_1736543549.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,064 F1 · shares: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on January 4, 2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.91 - $24.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 21:09 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,174 | $25.45 | $106,228.30 |
DisclosureSEC source: 0001764013-24-000194 · wk-form4_1732309782.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,169 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.91 - $25.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:27 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,271 | $28.79 | $94,172.09 |
DisclosureSEC source: 0001764013-24-000171 · wk-form4_1729283253.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,343 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on October 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.31 - $29.14 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 20:04 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 5,162 | $29.56 | $152,588.72 |
DisclosureSEC source: 0001764013-24-000166 · wk-form4_1728677055.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,614 F1 · shares: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,938 of these RSUs vested on October 4, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.28 - $29.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:11 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 149 | $32.32 | $4,815.68 |
DisclosureSEC source: 0001764013-24-000158 · wk-form4_1724443899.xml · nonDerivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,776 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on August 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.28 - $32.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:11 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,619 | $31.84 | $115,228.96 |
DisclosureSEC source: 0001764013-24-000158 · wk-form4_1724443899.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,925 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on August 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 - $32.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 21:39 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 184 | $30.55 | $5,621.20 |
DisclosureSEC source: 0001764013-24-000135 · wk-form4_1721425179.xml · nonDerivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,544 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on July 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.30 - $30.84 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 21:39 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,939 | $29.64 | $87,111.96 |
DisclosureSEC source: 0001764013-24-000135 · wk-form4_1721425179.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,728 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 5,479 of these RSUs vested on July 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 - $30.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 09, 2024 Filed Jul 10, 2024 21:07 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,747 | $28.06 | $133,200.82 |
DisclosureSEC source: 0001764013-24-000127 · wk-form4_1720645649.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,667 F1 · shares: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on July 4, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.48 - $28.42 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:18 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,042 | $29.65 | $119,845.30 |
DisclosureSEC source: 0001764013-24-000099 · wk-form4_1716581887.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 355,414 F1 · shares: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on May 17, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.31 - $30.02 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 22:01 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,774 | $29.94 | $83,053.56 |
DisclosureSEC source: 0001764013-24-000079 · wk-form4_1713564051.xml · nonDerivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,456 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 21,916 of these RSUs vested on April 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.43 - $30.20 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 22:01 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 9,479 | $28.80 | $272,995.20 |
DisclosureSEC source: 0001764013-24-000079 · wk-form4_1713564051.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,230 F1 · shares: On April 12, 2023, the holder was granted 87,664 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 14, 2023, of which 21,916 of these RSUs vested on April 12, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.43 - $29.40 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 20:18 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,689 | $31.18 | $115,023.02 |
DisclosureSEC source: 0001764013-24-000073 · wk-form4_1712780298.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,709 F1 · shares: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,938 of these RSUs vested on April 4, 2024. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.73 - $31.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:27 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 68,723 | $0.00 Strike: $30.78 | $0.00 |
DisclosureSEC source: 0001764013-24-000046 · wk-form4_1712262419.xml · derivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,723 Underlying: Common Stock · 68,723 shares Expires 2034-04-02 F2 · derivative.exercise_date: The shares underlying the options will vest as to 25% of the shares on April 2, 2025 and the remainder will vest in 36 substantially equal monthly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 20:27 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 54,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-24-000046 · wk-form4_1712262419.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,398 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on April 2, 2025, and the remainder will vest in substantially equal installments on a quarterly basis over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:21 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,930 | $36.15 | $105,919.50 |
DisclosureSEC source: 0001764013-24-000041 · wk-form4_1708723240.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,420 F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on February 17, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.85 - $36.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 11, 2024 Filed Jan 12, 2024 21:34 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 834 | $42.43 | $35,386.62 |
DisclosureSEC source: 0001764013-24-000010 · wk-form4_1705095240.xml · nonDerivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 323,350 F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on January 4, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.17 - $42.81 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 11, 2024 Filed Jan 12, 2024 21:34 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,681 | $41.64 | $111,636.84 |
DisclosureSEC source: 0001764013-24-000010 · wk-form4_1705095240.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,184 F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on January 4, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.06 - $42.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 19:51 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 154 | $33.52 | $5,162.08 |
DisclosureSEC source: 0001764013-23-000144 · wk-form4_1700855509.xml · nonDerivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 326,865 F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $33.46 - $33.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 19:51 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,901 | $32.75 | $127,757.75 |
DisclosureSEC source: 0001764013-23-000144 · wk-form4_1700855509.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,019 F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 7,051 of these RSUs vested on November 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $32.43 - $33.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 20:11 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,557 | $36.92 | $168,244.44 |
DisclosureSEC source: 0001764013-23-000120 · wk-form4_1697055061.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,920 F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,938 of these RSUs vested on October 4, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $36.92 - $36.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 21:03 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1 | $20.89 | $20.89 |
DisclosureSEC source: 0001764013-23-000103 · wf-form4_169299740413055.xml · nonDerivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,477 F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on August 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 21:03 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 14,385 | $20.30 | $292,015.50 |
DisclosureSEC source: 0001764013-23-000103 · wf-form4_169299740413055.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,478 F1 · security: On August 17, 2022, the holder was granted 112,816 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on August 19, 2022, of which 28,204 of these RSUs vested on August 17, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.87 - $20.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| July 19, 2023 Filed Jul 20, 2023 20:35 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,725 | $24.94 | $67,961.50 |
DisclosureSEC source: 0001764013-23-000080 · wf-form4_168988534195460.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,863 F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on July 4, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| April 18, 2023 Filed Apr 19, 2023 20:15 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,423 | $15.27 | $52,269.21 |
DisclosureSEC source: 0001764013-23-000053 · wf-form4_168193529586441.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,588 F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,938 of these RSUs vested on April 4, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.08 - $15.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:22 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 113,821 | $0.00 Strike: $14.70 | $0.00 |
DisclosureSEC source: 0001764013-23-000040 · wf-form4_168150372133037.xml · derivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,821 Underlying: Common Stock · 113,821 shares Expires 2033-04-12 F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on April 12, 2024 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:22 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 87,664 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-23-000040 · wf-form4_168150372133037.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,011 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on April 12, 2024 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 13:16 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 4,499 | $16.75 | $75,358.25 |
DisclosureSEC source: 0001764013-23-000008 · wf-form4_167361579253284.xml · nonDerivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,347 F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on January 4, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.31 - $16.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 13:16 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 11 | $15.15 | $166.65 |
DisclosureSEC source: 0001764013-23-000008 · wf-form4_167361579253284.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,846 F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 8,937 of these RSUs vested on January 4, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 20:20 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 12,500 | $9.44 | $118,000.00 |
DisclosureSEC source: 0001764013-22-000128 · wf-form4_166569241491854.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,857 F1 · security: On October 15, 2021, the holder was granted 143,000 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 18, 2021, of which 25% of these RSUs vested on October 4, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs. F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.16 - $9.44 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:52 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 169,648 | $0.00 Strike: $4.99 | $0.00 |
DisclosureSEC source: 0001764013-22-000101 · wf-form4_166094233293811.xml · derivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,648 Underlying: Common Stock · 169,648 shares Expires 2032-08-17 F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on August 17, 2023 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:52 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 112,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-22-000101 · wf-form4_166094233293811.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,357 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on August 17, 2023 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 15:53 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 29,959 | $7.25 | $217,202.75 |
DisclosureSEC source: 0001764013-22-000011 · wf-form4_164191639600365.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,541 F1 · security: On October 4, 2021, the holder was granted 59,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on October 5, 2021. These RSUs vested in their entirety on January 1, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of these RSUs. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 21:11 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 333,000 | $0.00 Strike: $8.72 | $0.00 |
DisclosureSEC source: 0001764013-21-000108 · wf-form4_163459145674723.xml · derivative · entry 2 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,000 Underlying: Common Stock · 333,000 shares Expires 2031-10-15 F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on October 4, 2022 and the remainder of the shares underlying the options vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| October 15, 2021 Filed Oct 18, 2021 21:11 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 143,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000108 · wf-form4_163459145674723.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,500 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on October 4, 2022 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 16:07 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 59,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-21-000106 · wf-form4_163345002882992.xml · nonDerivative · entry 1 Barnett Eva Renee · CIK 0001883766 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,500 F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs"). F2 · shares: The RSUs vest in their entirety on January 1, 2022, subject to the Reporting Person providing continuous service to the Issuer as of such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.